New progress in immunotherapy for triple negative breast cancer in 2021

doi:10.3877/cma.j.issn.1674-0807.2022.03.001

Abstract

Abstract:

Breast cancer is the most common malignant tumor in Chinese women. The treatment of breast cancer is comprehensive treatment of surgery, radiotherapy, chemotherapy, endocrine therapy and biological therapy, requiring multidisciplinary cooperation. With accumulation of evidence-based practice, immunotherapy, as an important part of the biological therapy, is widely applied. We reviewed the current research of immunotherapy for triple negative breast cancer, summarized the relevant progress in 2021, and interpreted the advancement in this field.

Key words: Breast neoplasms, Immunotherapy, Chemotherapy, Molecular targeted therapy

Jun Zhang, Chongru Zhao, Qiang Liu. New progress in immunotherapy for triple negative breast cancer in 2021[J]. Chinese Journal of Breast Disease(Electronic Edition), 2022, 16(03): 133-137.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2022.03.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2022/V16/I03/133

Figures/Tables 1

References 38

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33.
[2]	Zou Y, Zou X, Zheng S, et al. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis[J]. Ther Adv Med Oncol, 2020, 12: 175 883 592 094 092.
[3]	Basu A, Ramamoorthi G, Jia Y, et al. Immunotherapy in breast cancer: Current status and future directions.[J]. Adv Cancer Res, 2019, 143: 295-349.
[4]	Dent R, Trudeau M, Pritchard K I, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15): 4429-4434.
[5]	Mayer IA, Zhao F, Arteaga CL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131[J]. J Clin Oncol, 2021, 39(23): 2539-2551.
[6]	Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2021, 22(2): 212-222.
[7]	Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, et al. Breast cancer immunotherapy: Current and novel approaches[J]. Int Immunopharmacol, 2021, 98: 107 886.
[8]	Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing[J]. Nature, 2014, 512(7513): 155-160.
[9]	Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial[J]. Ann Oncol, 2014, 25(8): 1544-1550.
[10]	Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer[J]. Cancer Immunol Res, 2014, 2(4): 361-370.
[11]	Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer[J]. Lancet Oncol, 2019, 20(3): e175-e186.
[12]	Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era[J]. BMC Med, 2019, 17(1): 90.
[13]	Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study[J]. J Clin Oncol, 2016, 34(21): 2460-2467.
[14]	Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404.
[15]	Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 499-511.
[16]	Bertucci F, Goncalves A. Immunotherapy in breast cancer: the emerging role of PD-1 and PD-L1[J]. Curr Oncol Rep, 2017, 19(10): 64.
[17]	Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion 130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59.
[18]	Emens LA, Adams S, Barrios CH, et al. LBA16 IMpassion 130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2020, 31: S1148.
[19]	Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828.
[20]	Miles DW, Gligorov J, André F, et al. LBA15 primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)[J]. Ann Oncol, 2020, 31: S1147-S1148.
[21]	Hayley V. Atezolizumab tnbc indication withdrawn by manufacturer after talks with FDA [EB/OL]. [2022-01-10]. URL
[22]	Fehrenbacher L, Cecchini RS, Geyer Jr CE, et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+[J]. J Clin Oncol, 2020, 38(5): 444-453.
[23]	Chick RC, Clifton GT, Hale DF, et al. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer[J]. Clin Immunol, 2021, 225: 108 679.
[24]	Liu J, Liu Q, Li Y, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial[J]. J Immunother Cancer, 2020, 8(1): e000696.
[25]	Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria[J]. Lancet, 2020, 396(10257): 1090-1100.
[26]	Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer[J]. N Engl J Med, 2010, 363(20): 1938-1948.
[27]	Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821.
[28]	Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288.
[29]	Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2022, 33(5): 534-543.
[30]	National Cancer Institute. Testing MK-3475 (Pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer [EB/OL]. [2022-01-10]. URL
[31]	Hoffmann-La R. A study comparing atezolizumab (anti PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer (IMpassion 030) [EB/OL]. [2022-01-10]. URL
[32]	Fondazione M. Neoadjuvant therapy in triple negative breast cancer with antiPDL1 (NeoTRIPaPDL1) [EB/OL]. [2022-01-10]. URL
[33]	NSABP Foundation Inc. Clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple-negative breast cancer followed after surgery by atezolizumab or placebo [EB/OL]. [2022-01-10]. URL
[34]	Shanghai Henlius Biotech. To evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as neoadjuvant therapy and HLX10 versus placebo as adjuvant therapy in patients with triple negative breast cancer (TNBC) [EB/OL]. [2022-01-10]. URL
[35]	Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer[J]. JAMA Oncol, 2019, 5(1): 74.
[36]	Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis[J]. Ann Oncol, 2021, 32(8): 983-993.
[37]	Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2): 178-186.
[38]	Liu J, Li Y, Li Q, et al. Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients[J]. Breast Cancer Res Treat, 2021, 186(3): 687-697.

试验名称	NCT编号	治疗方案		开始时间	结束时间	主要终点
试验名称	NCT编号	新辅助治疗	辅助治疗	开始时间	结束时间	主要终点
	NCT02954874^[30]		帕博利珠单克隆抗体(1年)比观察组	2016年11月	2026年5月	iDFS
IMpassion 030	NCT03498716^[31]	Atezo + P序贯Atezo + AC/EC比P序贯AC/EC	Atezo(1年)	2022年1月	2023年3月	iDFS
Neo TRIPaPDL1	NCT02620280^[32]	Atezo + nab-P + Cb比nab-P + Cb	AC/EC/FEC化疗方案(4个疗程)	2022年5月	2022年10月	EFS
	NCT03281954^[33]	Atezo + P + Cb序贯Atezo + AC	Atezo(1年)	2023年12月	2024年6月	pCR和EFS
	NCT04301739^[34]	HLX10 + nab-P + Cb序贯HLX10 + AC/EC比PBO + nab-P + Cb序贯PBO + AC/EC	HLX10(9个疗程)	2022年9月	2027年4月	pCR

试验名称	NCT编号	治疗方案		开始时间	结束时间	主要终点
试验名称	NCT编号	新辅助治疗	辅助治疗	开始时间	结束时间	主要终点
	NCT02954874^[30]		帕博利珠单克隆抗体(1年)比观察组	2016年11月	2026年5月	iDFS
IMpassion 030	NCT03498716^[31]	Atezo + P序贯Atezo + AC/EC比P序贯AC/EC	Atezo(1年)	2022年1月	2023年3月	iDFS
Neo TRIPaPDL1	NCT02620280^[32]	Atezo + nab-P + Cb比nab-P + Cb	AC/EC/FEC化疗方案(4个疗程)	2022年5月	2022年10月	EFS
	NCT03281954^[33]	Atezo + P + Cb序贯Atezo + AC	Atezo(1年)	2023年12月	2024年6月	pCR和EFS
	NCT04301739^[34]	HLX10 + nab-P + Cb序贯HLX10 + AC/EC比PBO + nab-P + Cb序贯PBO + AC/EC	HLX10(9个疗程)	2022年9月	2027年4月	pCR

Please choose a citation manager

Content to export